Lumavita raises $16.3M in series A financing
Basel, Switzerland-based Lumavita AG has completed a series A financing that raised 18.0 million Swiss francs ($16.3 million). Lead investors were Atlas Venture, BB Biotech Ventures and BioMedInvest.
The new firm is focused on worldwide development and commercialization of treatments for infectious diseases in women's health. The company's product portfolio includes FemiFect (pentamycin), a polyene macrolide with a unique spectrum of coverage for the treatment of vaginitis, and SPK-601, a first-in-class PC-PLC inhibitor for the potential treatment of infections caused by human papilloma virus and herpes simplex virus. FemiFect is already approved in Switzerland for the treatment of vaginitis and Lumavita anticipates an imminent launch.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze